BTIG affirms Merrimack Pharma (Nasdaq: MACK) with a Neutral rating following news that the company is undertaking a corporate restructuring.BTIG ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE